BioSpace News Archive

Burning Rock Biotech Limited is delighted to announce that our personalized Minimal Residual Disease product, CanCatch®, was enrolled in a prospective observational study.

The Foundation for the National Institutes of Health (FNIH) today announces study findings, published in Nature Medicine, demonstrating the effectiveness of noninvasive blood tests to diagnose nonalcoholic steatohepatitis (NASH).

Galectin Therapeutics Inc. (NASDAQ: GALT) announced today the Company will participate in the 9th Edition of the Paris NASH meeting, where a select group of international experts gather each year at the prestigious Institut Pasteur in Paris to discuss the latest scientific and clinical research developments in non-alcoholic steatohepatitis (NASH) and its complications, including liver cirrhosis.

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today showcased new data at the Exosome Based Therapeutic Development Summit 5th Annual Meeting held September 5-7, 2023 in Boston.

September 7th, 2023, the University of Birmingham and Acticor Biotech (Paris:ALACT) announce the full regulatory approval of LIBERATE clinical study.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) will present at the H.C. Wainwright 25th Annual Global Investment Conference, to be held virtually and in person on September 11-13, 2023, in New York City at the Lotte New York Palace Hotel.

A research team from the University of Central Florida and Hesperos, a pioneer in human-on-a-chip technology, has developed the first human model to study the effects of an opioid overdose and reversal with naloxone.

Alkermes plc announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 15, 2023.

Paratek Pharmaceuticals, Inc. announced that leading independent proxy advisor Institutional Shareholder Services Inc. has recommended that stockholders vote FOR the Company’s previously announced definitive agreement to be acquired by Gurnet Point Capital and Novo Holdings A/S.

Voyager Therapeutics, Inc. has entered into employment agreements with three newly-hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager.